"Prevention by Rolipram of Concanavalin A-Induced T-Cell-Dependent Hepatitis in Mice."

According to the authors' abstract of an article published in European Journal of Pharmacology, "Rolipram is a type IV phosphodiesterase inhibitor endowed with powerful immunomodulatory properties. In this study, we evaluated the effects of this drug on the development of the T-cell-mediated hepatitis inducible in mice by concanavalin A. The results indicated that prophylactic treatment with either 5 or 10 mg/kg rolipram injected intraperitoneally 24 h and 1 h prior to intravenous (i.v.) challenge with 20 mg/kg concanavalin A successfully ameliorated serological and histological signs of liver damage, so that the treated mice showed lower transaminase levels in the plasma and milder...

Want to see the full article?

• Purchase this article for only $3.00